IPSEN, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

Phase 2

Terminated

Conditions: Acromegaly

Interventions: Drug: BIM23B065

First Posted Date: 2017-02-07

Last Posted Date: 2019-03-08

Lead Sponsor: Ipsen

Target Recruit Count: 4

Registration Number: NCT03045302

Locations: 🇷🇸
Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia
🇺🇦
"Institute of Endocrinological Pathology named after Danilevskij V.Ya., AMS of Ukraine", Department of General Endocrinology, Kharkiv, Ukraine
🇺🇦
"Institute of Endocrinology and Metabolism named after V.P.Komisarenko, AMS Ukraine", Department of General Endocrinology, Kiev, Ukraine

and more 3 locations

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

Completed

Conditions: Prostate Cancer

First Posted Date: 2017-01-11

Last Posted Date: 2021-06-24

Lead Sponsor: Ipsen

Target Recruit Count: 510

Registration Number: NCT03017313

Locations: 🇪🇸
Hospital de Txagorritxu, Barakaldo, Spain
🇪🇸
Hospital Universitario Dr Negrín, Las Palmas De Gran Canaria, Spain
🇪🇸
Hospital de la Princesa, Madrid, Spain

and more 24 locations

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

Completed

Conditions: Lower Limb Spasticity

First Posted Date: 2017-01-11

Last Posted Date: 2020-12-19

Lead Sponsor: Ipsen

Target Recruit Count: 242

Registration Number: NCT03017729

Locations: 🇺🇸
Children's Hospital at Erlanger, Chattanooga, Tennessee, United States
🇺🇸
Utah Neuro Rehabilitation, Murray, Utah, United States
🇺🇸
Texas Children's, Plano, Texas, United States

and more 21 locations

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

First Posted Date: 2017-01-11

Last Posted Date: 2018-12-21

Lead Sponsor: Ipsen

Target Recruit Count: 22

Registration Number: NCT03017690

Locations: 🇺🇸
Oncology Specialists of Charlotte, Charlotte, North Carolina, United States
🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Ochsner Medical Center Kenner, Kenner, Louisiana, United States

and more 2 locations

Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy

Phase 3

Completed

Conditions: Digestive System Disease

Interventions: Drug: Klean-Prep®
Drug: Eziclen®/Izinova®

First Posted Date: 2017-01-02

Last Posted Date: 2021-03-02

Lead Sponsor: Ipsen

Target Recruit Count: 250

Registration Number: NCT03008460

Locations: 🇮🇹
Ospedale "Spirito Santo" U.D.C., Pescara, Italy
🇫🇷
Université de Picardie Jules Verne, Amiens, France
🇩🇪
Uniklinikum Essen, Essen, Germany

and more 21 locations

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

Phase 4

Completed

Conditions: Spastic Hemiparesis

Interventions: Biological: Botulinum toxin type A
Other: GSC

First Posted Date: 2016-11-21

Last Posted Date: 2022-09-28

Lead Sponsor: Ipsen

Target Recruit Count: 157

Registration Number: NCT02969356

Locations: 🇺🇸
University of Pittsburgh Medical Center, Physical Medicine and Rehabilitation, Pittsburgh, Pennsylvania, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇫🇷
Service de Médecine Physique et de Réadaptation, Bâtiment Tastet-Girard, Groupe Hospitalier Pellegrin, Bordeaux, France

and more 16 locations

Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours

Completed

Conditions: Gastrointestinal Neuroendocrine Tumours

First Posted Date: 2016-08-02

Last Posted Date: 2020-11-05

Lead Sponsor: Ipsen

Target Recruit Count: 199

Registration Number: NCT02853422

Locations: 🇪🇸
Hospital de La Princesa, Madrid, Spain
🇪🇸
ICO Girona, Girona, Spain
🇪🇸
Hospital General Univ. Ciudad Real, Ciudad Real, Spain

and more 29 locations

Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer

Completed

Conditions: Prostate Cancer

First Posted Date: 2016-08-02

Last Posted Date: 2018-12-21

Lead Sponsor: Ipsen

Target Recruit Count: 628

Registration Number: NCT02853409

Locations: 🇪🇸
Hospital Quirón Campo de Gibraltar, Cádiz, Spain
🇪🇸
H. San Juan de Dios, Córdoba, Spain
🇪🇸
H. Can Misses, Ibiza, Spain

and more 11 locations

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

Completed

Conditions: Acromegaly

First Posted Date: 2016-06-21

Last Posted Date: 2019-08-05

Lead Sponsor: Ipsen

Target Recruit Count: 115

Registration Number: NCT02807233

Locations: 🇪🇸
Hospital Univ. Príncipe de Asturias, Alcalá de Henares, Spain
🇪🇸
Hospital Univ. Nuestra Sra. Candelaria, Santa Cruz, Tenerife, Spain
🇪🇸
Complejo Hospitalario Univ. A Coruña, A Coruña, Spain

and more 36 locations

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours

Terminated

Conditions: Neuroendocrine Tumours

First Posted Date: 2016-06-02

Last Posted Date: 2018-12-21

Lead Sponsor: Ipsen

Target Recruit Count: 40

Registration Number: NCT02788578

Locations: 🇫🇷
IUCT Oncopole, Toulouse, France
🇮🇹
Unversità degli Studi di Messina, Messina, Italy
🇩🇪
Zentralklinil Bad Berka, Bad Berka, Germany

and more 9 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy